This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D81.1 | Synonyms: T-B- NK+ SCID, RAG1/RAG2 deficiency SCID, Omenn syndrome (some), T-B- cell-reduced severe combined immunodeficiency
The concept of severe combined immunodeficiency (SCID) was established in the 1950s when infants with fatal immunodeficiency accompanied by lymphopenia and thymic aplasia were reported in Switzerland. In 1968, Robert Good first succeeded in treating a SCID patient with bone marrow transplantation, opening a new horizon in treatment.
As lymphocyte subset analysis techniques advanced, a system for classifying SCID according to the presence or absence of T cells, B cells, and NK cells was established. The T-B-NK+ type is a form in which both T cells and B cells are deficient but NK cells are normal or increased, and it was shown in the 1990s to be caused mainly by defects in the RAG1 or RAG2 genes.
In 1990, Schatz and Baltimore discovered the RAG1 and RAG2 genes, which are essential for V(D)J recombination. In 1996, Villa et al. first reported that RAG1/RAG2 mutations cause T-B-NK+ SCID, and subsequently the diverse clinical spectrum of Omenn syndrome and partial loss-of-function RAG variants was elucidated.
In Korea, SCID patients are diagnosed and treated at a small number of tertiary medical institutions such as Seoul National University Hospital. Accurate statistics by type are lacking, but RAG1/RAG2-deficient patients have been cumulatively reported on the order of several dozen.
The most common cause of D81.1 is loss-of-function mutations in the RAG1 (Recombination Activating Gene 1, 11p13) or RAG2 (11p13) gene. RAG1/RAG2 proteins act as endonucleases that catalyze cleavage of antigen receptor genes during V(D)J recombination. Complete loss-of-function variants cause T-B-NK+ SCID, and partial loss-of-function variants cause a diverse clinical spectrum including Omenn syndrome.
The Artemis protein (DCLRE1C gene, 10p13) is involved in DNA repair during V(D)J recombination. Artemis deficiency also causes T-B-NK+ SCID and is characterized by increased cellular radiosensitivity.
Defects in the DNA-PKcs (PRKDC), Cernunnos/XLF (NHEJ1), and DNA Ligase IV (LIG4) genes can also cause T-B-NK+ SCID or a similar phenotype.
SCID due to RAG1/RAG2 defects follows an autosomal recessive mode of inheritance. The RAG1 and RAG2 genes are located side by side on the short arm of chromosome 11 (11p13).
Complete loss-of-function (null) variants of the RAG1/RAG2 genes cause T-B-NK+ SCID. Partial loss-of-function (hypomorphic) variants show various phenotypes, including ① Omenn syndrome: a form characterized by hyperactive T cells, erythroderma, eosinophilia, and high IgE, ② atypical SCID, and ③ combined immunodeficiency (CID).
The lower the residual RAG activity, the closer the phenotype is to typical SCID; the higher the residual activity, the more the form becomes Omenn syndrome or mild immunodeficiency.
The overall incidence of SCID is estimated at 1 per 50,000–100,000 newborns. T-B-NK+ SCID (including RAG defects) is known to account for about 20–30% of all SCID.
RAG1/RAG2 variants are distributed worldwide and are not limited to particular ethnicities or regions. There are reports that the frequency of RAG defects is high in some Islamic populations due to specific founder effects.
In Korea, SCID due to RAG1/RAG2 defects is reported extremely rarely. Patients registered under code D81.1 in the rare disease information of the Korea Disease Control and Prevention Agency (KDCA) are very few. Undiagnosed patients are expected to be identified if newborn screening is expanded.
T cells and B cells generate the variable regions that make up the T-cell receptor (TCR) and B-cell receptor (BCR, immunoglobulin), respectively, through recombination of V, D, and J gene segments (V(D)J recombination). The RAG1/RAG2 complex is the key enzyme that recognizes the recombination signal sequences (RSS) between the segments and cleaves the DNA.
With RAG1 or RAG2 defects, V(D)J recombination does not occur, so functional TCRs or BCRs cannot be formed. Immature T progenitor cells without a TCR are eliminated in the thymus by negative selection and cannot develop into mature T cells. Similarly, pro-B cells without a BCR in the bone marrow cannot develop into mature B cells. Because NK cells do not require V(D)J recombination, they develop normally, giving the NK+ phenotype.
Severe recurrent infections begin after 3–6 months of age (after maternal antibodies are depleted). Pneumonia (P. jirovecii, CMV, adenovirus), chronic diarrhea, oral candidiasis, skin infections, sepsis, etc. are the main symptoms. Because there may be fatal reactions even to normal vaccine viruses, live vaccines are absolutely contraindicated.
Omenn syndrome, which occurs with partial loss-of-function RAG variants, shows distinctive symptoms different from SCID. It is characterized by generalized erythroderma, alopecia, chronic diarrhea, lymphadenopathy, hepatosplenomegaly, eosinophilia, and hyper-IgE. Hyperactivated autoreactive T cells attack tissues.
Absence of the thymic shadow (chest X-ray), underdeveloped lymphoid tissue (underdeveloped tonsils, nonpalpable lymph nodes), failure to thrive. In Omenn syndrome, generalized erythroderma, alopecia, lymphadenopathy, hepatosplenomegaly are characteristic.
CBC shows a markedly decreased absolute lymphocyte count (normal infants <3000/μL). Flow cytometry shows marked reduction or absence of both T cells (CD3+) and B cells (CD19+), with NK cells (CD16+/CD56+) normal or increased. In Omenn syndrome, T cells are increased, but all have a hyperactivated memory phenotype (CD45RO+) and an extremely restricted repertoire.
Serum IgG, IgA, and IgM are all decreased (after 6 months of age, when maternal IgG is depleted). In Omenn syndrome, IgE is extremely high, and IgG, IgA, and IgM are decreased.
Reduced T-cell production is detected early through TREC quantification from dried blood spots. RAG-deficient SCID has extremely low or undetectable TRECs and screens positive.
To confirm B-cell deficiency, measuring kappa-deleting recombination excision circles (KREC) together with TREC allows more accurate classification of T-B-NK+ SCID.
When there is an affected sibling, blood is drawn immediately at birth, and lymphocyte subset testing and RAG1/RAG2 gene analysis are performed.
Flow cytometry confirms the number and proportion of T (CD3+), B (CD19+), and NK (CD16+/CD56+) cells. Measurement of TCR αβ/γδ subsets, CD4+/CD8+ ratio, naive T cells (CD45RA+). T-cell function tests (proliferative response to mitogen stimulation).
Sequencing of the RAG1 and RAG2 genes is the standard confirmatory method. When a RAG defect is suspected but the result is negative, a gene panel of V(D)J recombination-related genes such as Artemis (DCLRE1C), DNA-PKcs (PRKDC), LIG4, and NHEJ1, or whole exome sequencing (WES), is performed.
When there is a family history, prenatal diagnosis is made by analysis of the relevant gene after CVS or amniocentesis.
The curative treatment is HSCT. Early transplantation (before infections occur, before 3.5 months of age) gives the best results. An HLA-matched sibling donor is best; if unavailable, unrelated donor or haploidentical transplantation is performed. In RAG-deficient SCID, B-cell reconstitution tends to be slower than in ADA-SCID or γc-SCID, so long-term IVIG supplementation may be needed after transplantation.
Protective isolation, IVIG administration, and antibacterial·antifungal·antiviral prophylaxis. Live vaccines absolutely prohibited. Use of CMV-negative irradiated blood products.
In Omenn syndrome, immunosuppressive treatment before HSCT (cyclosporine, steroids) is needed to suppress tissue damage by hyperactive T cells.
Without HSCT, most die of infection within the first year of life.
When diagnosed early through newborn screening, overall survival after HSCT has improved to 90% or more. The prognosis is worse when transplantation is received after infections have progressed. RAG-deficient SCID may have incomplete B-cell reconstitution compared with other types (γc, JAK3 defects), so a higher proportion require long-term immunoglobulin supplementation.
Research on RAG1/RAG2 gene therapy is in progress, but it is not yet at the stage of clinical application.
TREC (+KREC)-based newborn screening aims at early diagnosis within the first few days of life and linkage to HSCT before infections occur.
When a sibling of an affected child is born, immediate genetic testing and immune function evaluation are performed. Prenatal genetic diagnosis is available for high-risk couples.
After diagnosis and until HSCT, no live vaccines, Pneumocystis jirovecii prophylaxis, regular IVIG administration, protective isolation, etc. are strictly implemented.